Literature DB >> 18528508

The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations.

James A Fagin1.   

Abstract

A new era of cancer therapy is now upon us, heralded by fundamental discoveries of disease-causing genetic mutations affecting the activity of protein kinases or other key proteins that can be blocked with reasonable specificity with small molecules. Important therapeutic advances are extending the lives of patients with cancers that were previously refractory to therapy. There are opportunities for significant breakthroughs in many cancer types, including thyroid cancers, which although comparatively rare represent a particularly compelling paradigm of disease that may be well suited for treatment with specific kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18528508      PMCID: PMC1863588     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  29 in total

1.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

Authors:  G H Fisher; S L Wellen; D Klimstra; J M Lenczowski; J W Tichelaar; M J Lizak; J A Whitsett; A Koretsky; H E Varmus
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 2.  Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Authors:  G D Demetri
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

3.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

Review 4.  Tyrosine kinases as targets in cancer therapy - successes and failures.

Authors:  Peter Traxler
Journal:  Expert Opin Ther Targets       Date:  2003-04       Impact factor: 6.902

Review 5.  Jeremiah Metzger Lecture. Targeted cancer therapy.

Authors:  J Mendelsohn
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

6.  Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1.

Authors:  Bin Ouyang; Jeffrey A Knauf; Kenneth Ain; Benjamin Nacev; James A Fagin
Journal:  Clin Endocrinol (Oxf)       Date:  2002-03       Impact factor: 3.478

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors:  Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

9.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

Authors:  Bhushan Nagar; William G Bornmann; Patricia Pellicena; Thomas Schindler; Darren R Veach; W Todd Miller; Bayard Clarkson; John Kuriyan
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Authors:  Francesca Carlomagno; Donata Vitagliano; Teresa Guida; Fortunato Ciardiello; Giampaolo Tortora; Giancarlo Vecchio; Anderson J Ryan; Gabriella Fontanini; Alfredo Fusco; Massimo Santoro
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

View more
  2 in total

Review 1.  Update: the status of clinical trials with kinase inhibitors in thyroid cancer.

Authors:  Samuel A Wells; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

2.  The effect of near-infrared fluorescence conjugation on the anti-cancer potential of cetuximab.

Authors:  Ji Young Yun; Byung-Hwa Hyun; Sang Yoon Nam; Young Won Yun; Hu-Jang Lee; Beom-Jun Lee
Journal:  Lab Anim Res       Date:  2018-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.